Declining ALS Patients Are Waiting On The FDA...

As the war with Iran drags out and oil prices remain turbulent, it raises the question of whether — and how — prolonged conflict in the Middle East might impact global fossil fuel dependence and the future of renewable energy. On today’s Big Take podcast, Bloomberg reporter Todd ...  Show more

In Episode 6 of The Sixth Bureau, a series from The Big Take, with spy Xu Yanjun in prison, the US government pursues some of his collaborators. Plus, host Jordan Robertson gets an unexpected call which leads to a big discovery. The Sixth Bureau from Bloomberg News follows an MSS ...  Show more

When the F.D.A. approved the drug Aduhelm, the first Alzheimer’s treatment to receive the agency’s endorsement in almost two decades, it gave hope to many.

But the decision was contentious; some experts say there’s not enough evidence that the treatment can address cogni ...

Aduhelm, known generically as aducanumab, is the first drug to actually affect the underlying disease process associated with Alzheimer's. Yet sales have been limited, and the drug is reaching very few patients — at least so far. It's expensive, risky and likely doing little to i ...  Show more

For decades, the law has sought to restrain nursing homes from trying to control the behavior of dementia patients with antipsychotic drugs, which are known to have adverse health effects. 

An alarming rise in schizophrenia diagnoses suggests some homes have found a way ...